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Abstract
Low and high-grade ductal carcinoma in-situ (DCIS) are known to be highly disparate by a multitude
of parameters, including progression potential, immunophenotype, gene expression profile and
DNA ploidy. In this study, we analyzed a group of intermediate and high-grade DCIS cases to
determine how well the core biopsy predicts the maximal pathology in the associated excisions,
and to determine if there are any core biopsy morphologic features that may predict a close (≤ 0.2
cm) or positive margin in the subsequent excision. Forty-nine consecutive paired specimens [core
biopsies with a maximal diagnosis of DCIS, and their corresponding excisions, which included 20
and 29 specimens from mastectomies and breast conserving surgeries respectively] were evaluated
in detail. In 5 (10%) of 49 cases, no residual carcinoma was found in the excision. In another 4 cases,
the changes were diagnostic only of atypical ductal hyperplasia. There were 4 and 3 respective cases
of invasive and microinvasive carcinoma out of the 49 excision specimens, for an overall invasion
frequency of 14%. In 28 cases where a sentinel lymph node evaluation was performed, only 1 was
found to be positive. Among the 40 cases with at least residual DCIS in the excision, there were 5
cases in which comedo-pattern DCIS was present in the excision but not in the core biopsy,
attributed to the lower maximal nuclear grade in the biopsy proliferation in 4 cases and the absence
of central necrosis in the 5th. For the other main histologic patterns, in 8 (20%) of 40 cases, there
were more patterns identified in the core biopsy than in the corresponding excision. For the other
32 cases, 100%, 66%, 50%, 33% and 25% of the number of histologic patterns in the excisions were
captured in 35%, 5%, 17.5%, 15% and 7.5% of the preceding core biopsies respectively. Therefore,
the core biopsy reflected at least half of the non-comedo histologic patterns in 77.5% of cases. In
6(15%) of the 40 cases, the maximum nuclear grade of the excision (grade 3) was higher than that
seen in the core biopsy (grade 2). Overall, however, the maximum nuclear grade in the excision
was significantly predicted by maximum nuclear grade in the core biopsy (p = 0.028), with a Phi of
0.347, indicating a moderately strong association. At a size threshold of 2.7 cm, there was no
significant association between lesional size and core biopsy features. Furthermore, the clear
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margin width of the cases with lesional size ≤ 2.7 cm (mean 0.69 cm) was not significantly different
(p = 0.4) from the cases with lesional size > 2.7 cm (mean 0.56 cm). Finally, among a variety of core
biopsy features that were evaluated, including maximum nuclear grade, necrosis, cancerization of
lobules, number of tissue cores with DCIS, number of DCIS ducts per tissue core, total DCIS ducts,
or comedo-pattern, only necrosis was significantly associated with a positive or close (≤ 0.2 cm)
margin on multivariate analysis (Phi of 0.350). It is concluded that a significant change [to invasive
disease (14%) or to no residual disease (10%)] is seen in approximately 24% of excisions that follow
a core biopsy diagnosis of intermediate or high-grade DCIS. Core biopsy features are of limited
value in predicting a close or positive margin in these lesions.
Introduction
Ductal carcinoma in-situ (DCIS) of the breast is com-
prised of a heterogeneous spectrum of intraductal epithe-
lial proliferations that are considered the probable
precursor lesions to most invasive breast carcinomas
[1,2]. The widespread implementation of screening mam-
mography programs has resulted in a dramatic increase in
the incidence of DCIS during the past few decades [3-8].
Whereas most DCIS in the pre-mammographic eras were
of the comedo-type, screening-detected DCIS tend to be of
a comparatively smaller size and lower grade [9].
Although low-grade and high-grade are unified by the fact
that both are intraepithelial proliferations that are breast
cancer precursors, they are considered to be substantially
different processes. Low-grade DCIS is generally positive
for the estrogen & progesterone receptors (ER & PR) and
negative for HER2/neu, displays chromosomal losses at
16q, gains in 1q and near euploidy [10,11]. High-grade
DCIS, in contrast, tends to display lack of expression of ER
and PR, HER2/neu overexpression/amplification, a multi-
tude of chromosomal changes, and aneuploidy [10,11].
Expectedly, intermediate grade DCIS displays changes
that are intermediate between these two extremes [10].
Detailed evaluations of the protein expression patterns of
DCIS of various grades and a comparison of such patterns
with those of their synchronous invasive cancers, typically
show strong correlations in a grade-dependent pattern
[12]. Furthermore, progression from low-grade to high-
grade DCIS is considered to be, at most, a very infrequent
event [13]. Therefore, in one contemporary model of the
evolution of invasive ductal breast carcinomas, well-dif-
ferentiated ductal carcinomas evolve from low-grade
DCIS whereas poorly differentiated invasive ductal carci-
nomas evolve from high-grade DCIS, with minimal, if
any, overlap [11,13]. The present study focused on DCIS
lesions that are not on the lower end of the spectrum to
obtain a better understanding of this specific group.
Several aspects of the management of patients with DCIS
have engendered significant discussions in the recent
medical literature, most notably (for the present pur-
poses), the excision modality (breast conserving surgery
versus mastectomy), the necessity of adjuvant radiother-
apy and the necessity of sentinel lymph node sampling.
[14-17]. Some of these controversies are centered, at least
in part, on concerns about the ability of pre-definitive sur-
gery measures, such as imaging and core biopsy, to predict
the maximal pathology in the patient (i.e. maximal DCIS
grade, presence or absence of stromal invasion, and hence
axillary lymph node status). In this study, we analyze a
group of intermediate and high-grade DCIS cases to deter-
mine how well the core biopsy predicts the maximal
pathology in the associated excisions, and to determine if
there are any core biopsy morphologic features that may
predict a close or positive margin in the subsequent exci-
sions.
Methods
Core Biopsies
Following approval from our institutional review board
(protocol FWH 20090088H), the computerized patho-
logic database of Wilford Hall Medical Center (Lackland
AFB, TX) was searched for all core breast biopsies diagnos-
tically coded as ductal carcinoma in situ for the period
between January 2006 and January 2009. Cases were
excluded if a concurrent invasive or microinvasive carci-
noma was diagnosed in the core biopsy and/or a follow-
up excision was not available in our records for review. All
slides for the core biopsies were reviewed in detail by 2
authors (OF and NFC), and the following items were
recorded for each case: 1) range of nuclear grades and
maximal nuclear grade (figure 1ac); 2) histologic patterns
of DCIS (i.e. solid, micropapillary, cribriform, clinging,
papillary etc, figures 1df &2ab); 3) Presence or absence of
central necrosis; 4) Presence or absence of DCIS-associ-
ated calcification; 5) Number of tissue cores obtained, as
counted on the glass slides; 6) Number of cores with at
least one focus with changes diagnostic of DCIS, 7) Pres-
ence or absence of lobular cancerization by DCIS (figure
2c); 8) Number of DCIS ducts (ductal cross-sectional pro-
files of DCIS, vida infra; figure 2d); 9) Type of radiological
guidance for biopsy. Nuclear grade was assigned using a
modification of the 3-tiered scale employed in the modi-
fied Scarff Bloom Richardson (MSBR) system for grading
invasive breast cancers [18]. Grade 1 nuclei were generally
monomorphic and displayed rounded contours, evenlyDiagnostic Pathology 2009, 4:26 http://www.diagnosticpathology.org/content/4/1/26
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dispersed chromatin whose overall effect is to result in a
vaguely hyperchromatic appearance, and inconspicuous
nucleoli (figure 1a). Grade 3 nuclei displayed marked
nuclear pleomorphism, and cases with grade 3 nuclei
were typically characterized by a 3-fold or greater varia-
tion in nuclear size and shape (figure 1c). Grade 2 nuclei
displayed prominent nucleoli, irregular distributed chro-
matin and a level of pleomorphism that was intermediate
between grade 3 and grade 1 nuclei (figure 1b). Cross sec-
tional profiles of DCIS were counted individually in every
tissue core and added (figure 2d). When it could be clearly
determined that a focus of interest represented DCIS can-
cerization of a single terminal ductolobular unit (figure
2c), only 1 cross sectional profile was counted for the
whole focus. Unless otherwise specified, the term "solid
pattern" is used herein as a generic descriptor for an intra-
ductal epithelial proliferation that fills the duct and which
lacks micropapillary and cribriform areas, irrespective of
its other features. As such, it encompasses the lesions that
have traditionally being referred to as displaying the
"comedo-pattern DCIS" or "comedo-DCIS". Comedo-
pattern DCIS was defined as solid pattern DCIS with cen-
tral necrosis and grade 3/3 atypia (figure 1e). By defini-
tion, this study only included cases with intermediate or
high-grade DCIS in the core biopsy and/or the corre-
sponding excision. Cases of intermediate grade DCIS were
characterized by grade 1/3 nuclear atypia with necrosis, or
grade 2/3 nuclear atypia irrespective of necrosis status.
Cases of high-grade DCIS were characterized by grade 3/3
nuclear atypia with or without necrosis.
Excisions
Slides for the excisions associated with the aforemen-
tioned core biopsies were similarly reviewed. The follow-
ing items were recorded for each case: 1) range of nuclear
grades and maximal nuclear grade; 2) histologic patterns
of DCIS, 3) Presence or absence of central necrosis in an
otherwise solid pattern; 4) Presence or absence of necrosis
in other histologic patterns; 5) Presence or absence of
DCIS-associated calcification; 5) Type of excision (breast-
conserving surgery [BCS] or mastectomy); 7) Specimen
size in 3 dimensions; 8) Number of paraffin-embedded
blocks of breast tissue processed; 9) Number of processed
blocks with DCIS; 10) Size of DCIS, which was deter-
mined using the recently reported findings of Dadmanesh
et al [19]  0.4 cm multiplied by number of blocks with
DCIS; 11) Presence or absence of invasive or microinva-
a-c: Three-tiered nuclear grading system showing grade  1(1a), grade 2 (1b) and grade 3 (1c) cytologic features Figure 1
a-c: Three-tiered nuclear grading system showing 
grade 1(1a), grade 2 (1b) and grade 3 (1c) cytologic 
features. d: Solid pattern ductal carcinoma in-situ with 
grade 2/3 atypia and microcalcification (upper left field), and 
solid pattern ductal carcinoma in-situ with central necrosis 
and nuclear grade 2/3 (lower right field). e: Solid pattern duc-
tal carcinoma in-situ with grade 3/3 atypia and central necro-
sis (comedo-pattern ductal carcinoma in-situ). f: Cribriform 
pattern ductal carcinoma in-situ with grade 2/3 atypia and 
foci of necrosis.
a
def
bc
a: Clinging pattern ductal carcinoma in-situ Figure 2
a: Clinging pattern ductal carcinoma in-situ. b: Micro-
papillary pattern ductal carcinoma in-situ. c: Cancerization of 
lobules by ductal carcinoma in-situ. d: As an example of the 
counting system for ductal carcinoma in-situ ducts, 6 ducts 
would be counted in this microscopic field.
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sive carcinoma; 12) regional lymph node status; 13)
Duration between biopsy and excision; 14) Margin status,
with a "clear" margin width defined as the linear distance,
as measured microscopically, between a DCIS duct and
the closest inked margin for that case. All microscopic
measurements were made on a BX45 microscope (model
U-DO3; Olympus Corporation, Tokyo, Japan). In cases
with "positive" margins, the aforementioned "linear dis-
tance" was 0 cm. A "close" margin was defined as ≤ 0.2
cm.
Statistics
Statistical analyses were performed using SPSS for Win-
dows, release 11.5.0 (SPSS Inc., Chicago, IL). Descriptive
statistics were prepared for the above mentioned varia-
bles. Strength of association between individual variables
recorded in the core biopsy and excision (BCS and mastec-
tomy) were measured using Pearson chi-square, Fisher's
exact test, and Phi. In order to determine whether any sin-
gle variable or group of variables predicts a close margin
in subsequent excision, linear regression and binary logis-
tic regression were used. Associational analyses were per-
formed on all qualifying cases with residual carcinoma in
the subsequent excision, as well as on cases separated into
BCS and mastectomy groups.
Results
A total of 49 paired biopsy/excisions specimens ("cases")
from 47 patients were reviewed (2 patients each with
bilateral disease and hence bilateral specimen pairs).
There was an average of 33.4 (± 11) days between biopsies
and excisions (1072; median 30).
Core Biopsies
Core biopsies were ultrasound and stereotactic-guided in
7 and 41 cases respectively. Guidance was unknown in the
49th case. Indications were predominantly for mammo-
graphic abnormalities (mass lesion & calcifications in 3
cases, non-specific area of enhancement in 1 case, and cal-
cifications only in the remaining cases). An average of 9.1
(± 4.7) tissue cores per case was processed (1 to 25;
median 8). DCIS was present in an average of 4.4 (± 2.4)
tissue cores per case (111; median 4). DCIS ducts ranged
in number from 4 to 117 (mean 26.4) in these cores. Can-
cerization of lobules by DCIS was identified in 23 (47%)
of 49 cases. DCIS-associated calcification was present in
40 (81.6%) of 49 cases. A comedo-pattern DCIS (solid
with central necrosis and nuclear grade 3/3) was present
in 16 cases. The frequency and distribution of the various
histologic patterns in the subset of cases associated with
residual disease in the excision are outlined in Table 1.
Excisions
Twenty (41%) and 29 (59%) of the excisions were prod-
ucts of mastectomies and various permutations of breast
conserving surgeries (BCS), respectively. There was no
residual carcinoma in 9 (18.4%) of 49 cases. Four
(44.4%) of these 9 cases had changes diagnostic of atypi-
cal ductal hyperplasia (including one case that was re-clas-
sified from atypical lobular hyperplasia), whereas no
atypical proliferations were present in the remaining five.
The remaining 40 cases were comprised of specimens
from 18 mastectomies and 22 BCS. The average specimen
sizes (maximal dimensions) for the mastectomy and BCS-
associated specimens were 19.6 cm (± 4.08) and 9.36 cm
(± 2.5) respectively. A per-case average of 27 (± 11.9) tis-
sue sections was processed from the 40 cases (1060;
median 24). For the 18 mastectomy specimens, an aver-
age of 24.6 (± 9.4) sections was processed per case (1044;
median 22.5). For the BCS-associated specimens, an aver-
age of 29.09 (± 13.4) sections was processed per case
(1260; median 25.5). Overall, an average of 7.52 (± 5)
Table 1: A comparison of biopsies and excisions regarding the frequency of selected pathologic features of DCIS**
Morphologic features Core biopsy
(n = 40)
Excision
(n = 40)
Maximum nuclear grade 3 18 19
Maximum nuclear grade 2 22 21
Necrosis in DCIS 33 29
Calcification in DCIS 32 29
Comedo-pattern necrosis present (Solid pattern with central necrosis and grade 3/3 nuclear atypia) 16 14
Non-comedo pattern necrosis present (associated with grade 2/3 atypia and/or non-solid patterns) 17 16
Solid pattern only (irrespective of atypia or necrosis) 17 8
Solid and micropapillary only 01
Solid, micropapillary, and cribriform only 7 5
Micropapillary only 10
Micropapillary and clinging 10
Cribriform only 01
Micropapillary and cribriform only 21
Solid, micropapillary, clinging and cribriform only 0 3
Clinging only 00
DCIS ductal carcinoma in-situ; **excludes cases in which no residual DCIS was found in the excision.Diagnostic Pathology 2009, 4:26 http://www.diagnosticpathology.org/content/4/1/26
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sections per case had DCIS (120; median 7), including an
average of 6.4 (± 3.9) sections in the BCS-associated spec-
imens and average of 8.9 (± 5.9) sections in the mastec-
tomy specimens.
Biopsies and excisions
There were 4 cases of invasive carcinoma and 3 examples
of microinvasive carcinoma out of the 49 excision speci-
mens that were evaluated, for an overall invasion fre-
quency of 14%. The 4 cases included 1 mucinous and 3
ductal (not otherwise specified) carcinomas, and all were
grade II/III by MSBR criteria. Axillary lymph nodes were
also positive in 1 of these 4 cases (2 of 4 lymph nodes
removed as part of sentinel node evaluation; 1 metastatic
deposit > 0.2 cm and the other < 0.2 cm). Of the 28 cases
in which a sentinel lymph node evaluation was per-
formed, this was the only case with a positive node. As
previously noted, in 5 (10.2%) of 49 cases, no residual
carcinoma was found. In another 4 cases, the changes
were diagnostic only of atypical ductal hyperplasia
Among the 40 cases with residual disease, the histologic
patterns identified singly or in various combinations were
micropapillary, clinging, cribriform, and solid  the latter
including the comedo-pattern. There were 5 cases in
which comedo-pattern DCIS was present in the excision
but not in the core biopsy. The discrepancy was attributed
to lower maximal nuclear grade in the biopsy prolifera-
tion in 4 cases and the absence of central necrosis in the
5th. When necrosis is considered in general (i.e. irrespec-
tive of whether it is specifically in association with the
comedo-pattern), there were also 5 cases in which this
finding was present in the excision but absent in the pre-
ceding biopsy. In 6 (15%) of the 40 pairs, calcification
was present only in the excision specimens, For the other
histologic patterns, in 8 (20%) of 40 cases, there were
more histologic patterns identified in the core biopsy than
in the corresponding excision. For the other 32 cases,
there was general, albeit varying degrees of agreement
between the core biopsies and the excisions. For the core
histologic patterns, i.e. solid, micropapillary, cribriform,
and clinging, 100%, 66%, 50%, 33% and 25% of the
number of histologic patterns in the excisions were cap-
tured in 14 (35%), 2 (5%), 7 (17.5%), 6 (15%) and 3
(7.5%) of these 32 core biopsies respectively. Therefore,
the core biopsy captured at least half of the core non-
comedo histologic patterns in 77.5% of cases. These asso-
ciations were not reflected upon statistical analysis: Pear-
son chi-square showed that among the histologic types of
DCIS, only the presence of a cribriform pattern in the core
biopsy significantly predicted the presence of a cribriform
pattern in the excision (p = 0.028), with a Phi of 0.348,
indicating a moderately strong association; this associa-
tion did not hold with Fisher's exact test on the separate
BCS and mastectomy groups
A general level of congruence between core biopsies and
excisions was observed regarding maximal nuclear grade.
Parenthetically, all 40 cases were either maximum nuclear
grade 2 (n = 22) or 3 (n = 18). As such, there were 22 and
18 cases of intermediate and high-grade DCIS respec-
tively. In 6 (15%) of the 40 cases, the maximum nuclear
grade of the excision (grade 3) was higher than that seen
in the core biopsy (grade 2). Pearson chi-square showed
that maximum nuclear grade in the excision was signifi-
cantly predicted by maximum nuclear grade in the core
biopsy (p = 0.028), with a Phi of 0.347, indicating a mod-
erately strong association. Again, this association did not
hold with Fisher's exact test on the separate BCS and mas-
tectomy groups. Other features that were evaluated,
including calcification, necrosis, non-cribriform histo-
logic pattern, and range of nuclear grades did not show a
statistically significant correlation between the core
biopsy and subsequent excision, either globally or within
separate BCS and mastectomy groups, which may be
related to our small sample size.
Margin status in excisions and core biopsy features
The average clear margin width for all 40 cases was 0.63
cm (± 0.96; 04.5 cm; median 0.2 cm), including 6 cases
with positive margins, 21 cases with clear margin width ≤
0.2 cm, and 19 cases with clear margin width > 0.2 cm. For
the 22 specimens associated with BCS, the average clear
margin width was 0.35 cm (± 0.41; 01.5 cm; median 0.15
cm), including 5 cases with positive margins, 13 cases
with clear margin width ≤ 0.2 cm, and 9 cases with clear
margin width > 0.2 cm. For the 18 mastectomy-associated
specimens, the average clear margin width was 0.97 cm (±
1.30; 04.5 cm; median 0.35 cm), including 1 case with
positive margins, 8 cases with clear margin width ≤ 0.2
cm, and 10 cases with clear margin width > 0.2 cm. On
univariate and multivariate analysis, the only core biopsy
variable which significantly predicted a close margin on
excision was the presence of necrosis (p = 0.027), with a
Phi of 0.350, indicating a moderately strong correlation.
This association did not hold when evaluated on separate
BCS and mastectomy groups. No other significant associ-
ation between core biopsy features, including maximum
nuclear grade, comedo-pattern present, cancerization of
lobules, number of tissue cores processed, DCIS ducts per
tissue core, number of tissue cores with DCIS or other his-
tologic patterns, and margin status was identified at the ≤
versus > 0.2 cm threshold (Table 2)
Tumor size in excisions and core biopsy features
The average DCIS lesional size, as determined by multi-
plying 0.4 cm by number of blocks with DCIS [19], was
3.01 cm (± 1.99) (range 0.48 cm; median 2.8 cm). There
was no significant difference regarding lesional size
between the mastectomy specimens [mean 3.56 cm (±
2.34); median 3.6 cm] and the BCS-associated specimensDiagnostic Pathology 2009, 4:26 http://www.diagnosticpathology.org/content/4/1/26
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[mean 2.56 cm (± 1.55); median 2.6 cm]. The average
DCIS size was used to classify the 40 cases into two groups
for analytical purposes. The first group was comprised of
all cases with lesional size in the excision ≤ 2.7 cm (n =
22) whereas the lesional size was greater than 2.7 cm in
the 18 cases that constituted the other group. At this size
threshold, there was no significant association between
lesional size in excisions and core biopsy features
(number of DCIS ducts, DCIS ducts per tissue core,
number of tissue cores with DCIS, and cancerization of
lobules; Table 3). Furthermore, the clear margin width of
the cases with lesional size ≤ 2.7 cm (mean 0.69 cm) was
not significantly different from the cases with lesional size
> 2.7 cm (mean 0.56 cm).
Discussion
In the current environment, wherein screening-detected,
calcification-associated, and impalpable DCIS are more
frequently encountered, the core biopsy has emerged as
an excellent modality for the preoperative establishment
of the diagnosis and for the optimization of therapeutic
options [20,21]. Nonetheless, the core biopsy is associ-
ated with a somewhat higher inaccuracy rate for the diag-
nosis of DCIS than for the diagnosis of invasive cancer
[22,23]. In the study of Dillon et al [22], for example, the
initial core biopsy was not fully diagnostic in 33% and
26% of their cases of intermediate and high-grade DCIS,
respectively. Previous studies have evaluated the signifi-
cance of DCIS size, extent, and histologic features in core
biopsies as a predictor of margin status in the subsequent
excisions [24-27]. However, these studies were centered
on cases of DCIS admixed with invasive carcinoma. There
is very limited published data on a potential correlation
between the pathologic features of pure DCIS in core
biopsies and margin status. The goals of the present study
are two-fold: 1) To determine if there are any core biopsy
morphologic features that may predict a close or positive
margin in the subsequent excision in a group of interme-
Table 2: Relationship between core biopsy features and margin status (univariate analysis)**
Overall (n = 40) Breast conserving surgery specimens (n = 22), 
margin status
Mastectomy specimens (n = 18), margin 
status
Core biopsy 
features
≤ 0.2 cm
(n = 21)
> 0.2 cm
(n = 19)
p ≤ 0.2 cm
(n = 13)
> 0.2 cm
(n = 9)
p ≤ 0.2 cm
(n = 8)
> 0.2 cm
(n = 10)
p
Maximum nuclear 
grade 3/3
(n = 18)
991 331 661
Maximum nuclear 
grade 2/3
(n = 22)
12 10 0.76 10 6 0.29 240.57
Necrosis present
(n = 33)
16 17 1 10 8 0.74 690.47
Comedo-pattern 
present
(n = 16)
881 32NA 561
Cancerization of 
lobules present
(n = 21)
91 2 0.54 451 570.68
Number of tissue 
cores processed 
(mean)
8.6 9.4 0.56 9.4 8.4 0.66 7.25 10.3 0.08
DCIS ducts per 
tissue core (mean)
5.9 6.1 0.85 64 . 2 0.17 5.9 7.9 0.35
Number of tissue 
cores with DCIS
4.42 5.05 0.45 4.23 3.89 0.68 4.75 6.1 0.31
Total DCIS ducts 
(mean)
25.9 31.4 0.49 23.1 17.6 0.35 30.25 43.9 0.4
Solid Pattern 
present
(n = 37)
20 17 0.64 13 7 0.11 71 0 0.49
Micropapillary 
pattern present
(n = 10)
640.66 32NA 32NA
Cribriform 
pattern present
(n = 18)
81 0 0.53 551 350.62
Clinging pattern 
present
(n = 4)
31NA 01NA 30NA
DCIS ductal carcinoma in-situ; **excludes cases in which no residual DCIS was found in the excision; NA not applicableDiagnostic Pathology 2009, 4:26 http://www.diagnosticpathology.org/content/4/1/26
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diate and high-grade DCIS cases, and 2) To determine
how well the core biopsy predicts the maximal pathology
in the associated excisions.
Although there is no consensus of what constitutes a
"close" margin [28], there is a near consensus that the sta-
tus of margins after an excision for DCIS is a strong pre-
dictor of residual disease and/or local recurrence [29-34].
As such, there have been a variety of proposals that are
aimed at establishing the adequacy of the excision intra-
operatively, including intraoperative specimen ultra-
sonography, intraoperative specimen mammography,
gross specimen examination, the routine sampling of the
"cavity margins" around the initial excision, and frozen
section evaluation of margins [35-39]. While mammo-
graphic features, such as linear branching calcification,
accurately identify many examples of high-grade DCIS as
such [40,41], this modality does not do so invariably [42],
and may underestimate lesional size and extent, especially
in non-comedo DCIS [43-45]. It may therefore be of clin-
ical utility to have core biopsy features that may predict
the necessity for a more generous excision during the ini-
tial surgery, which in addition to the aforementioned rea-
sons, may also help stratify those patients that would
qualify for specific therapies that require negative margins
such as accelerated, hypofractionated whole breast radio-
therapy [46] or partial breast intraoperative radiation
[47]. Furthermore, in addition to histologic grade and
margin status, it has been shown that several other patho-
logic features in the excision specimens may be associated
with local recurrence [48-51]. Among these are volume of
DCIS near margins and the overall DCIS volume in the
specimen  whether deduced from the number of slides
with DCIS, number of DCIS ducts or DCIS-cancerized
lobules, or percentage of blocks with DCIS [48-51]. If any
core biopsy features can predict a large volume in the exci-
sion, this may also be of clinical utility.
Our study shows that of all the core biopsy features that
were evaluated, including maximum nuclear grade, necro-
sis, cancerization of lobules, number of tissue cores with
DCIS, number of DCIS ducts per tissue core, total DCIS
ducts, comedo-pattern or other histologic patterns, only
necrosis was significantly associated with a positive or
close margin on univariate and multivariate analysis. Sim-
ilarly, at the 2.7 cm size threshold, there was no significant
correlation between lesional size in excisions and selected
core biopsy features (number of DCIS ducts, DCIS ducts
per tissue core, number of tissue cores with DCIS, and
cancerization of lobules). Most of the core biopsy features
evaluated herein are therefore of limited value in predict-
ing close or positive margins, or large lesional size in inter-
mediate and high-grade DCIS. Our findings, however,
need to be confirmed in substantially larger datasets from
multiple institutions.
The second goal of this study was to determine how well
the core biopsy predicted the maximal pathology in the
patient, as evaluated in the subsequent excisions in this
specific dataset of intermediate and high-grade DCIS.
Regarding the risk of invasive disease in a core biopsy
showing DCIS alone, previous studies of pan-grade DCIS
have shown that invasive disease is present in 8 to 36% of
cases [52-57]. In high-risk subsets, i.e. those patients with
large masses, numerous mammographic calcifications,
DCIS of high histologic grade, or presentation with a pal-
pable mass, this risk is approximately 41.5 to 48%
[58,59]. In our own dataset, we identified 4 examples of
invasive carcinoma and 3 examples of microinvasive car-
cinoma out of the 49 excision specimens that we evalu-
ated. Therefore, the risk of any kind of invasive disease in
our patient population after a core biopsy diagnosis of
intermediate or high-grade DCIS is somewhat low at 14%
(7/49). There were too few cases of invasive disease to
stratify for preoperative findings that may potentially pre-
dict invasion. The reverse corollary is that in 5 (10.2%) of
49 cases, no residual carcinoma was found. In another 4
cases, the changes were diagnostic only of atypical ductal
hyperplasia. A recent report on 40,395 screening detected
breast malignancies showed that in 174 cases no carci-
Table 3: Lack of significant correlation between selected core biopsy features and lesional size in excisions (at the ≤ 2.7 cm versus > 2.7 
cm threshold)
Core Biopsy features Lesional size in excision ≤ 2.7 cm
(n = 22)
Lesional size in excision > 2.7 cm
(n = 18)
P
Total DCIS ducts
(means)
25.3 28.0 NS
Number of tissue cores with DCIS
(means)
5.1 4.4 NS
DCIS ducts per tissue core
(means)
5.01 6.3 NS
Cancerization of lobules present 12 8 NS
DCIS: ductal carcinoma in-situ
NS: Not significantDiagnostic Pathology 2009, 4:26 http://www.diagnosticpathology.org/content/4/1/26
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noma was identified in the excision subsequent to the
core biopsy [60]. In 165 of these cases, the authors con-
cluded that the lesion was entirely removed in the core
biopsy, whereas the remaining 9 were considered to false
positive diagnoses in the biopsies [60]. Therefore, allow-
ing for differences in sample size and composite of
lesional types, our rate of finding no residual disease (5/
49; 10.2%) is higher but largely comparable to the
reported findings in that study (165/40,395; 4.3%).
The necessity for sentinel lymph node evaluation in
patients with pure DCIS, and whether patient subsets can
be preoperatively identified that would benefit the most
from this evaluation, continues to be controversial
[61,62]. Sentinel nodes are found to be positive in 4.8%
to 13% of patients with a core biopsy diagnosis of DCIS
[57,63-66]. Our findings provide insights into the fre-
quency of lymph node involvement in this group of inter-
mediate and high-grade DCIS. Amongst the subset of 28
patients that received any nodal evaluation, only 1 (3.6%)
had sentinel lymph node involvement. Parenthetically,
for this single patient, only touch preparations of the
lymph node's cut section were performed intraopera-
tively, and did not reveal malignant cells even upon their
detailed review in the aftermath. The malignant cells
became morphologically evident only after subsequent
additional node sectioning, when a "negative" intraoper-
ative diagnosis had already been rendered. As such, she
did not benefit from sentinel node evaluation. Our expe-
rience, therefore, is that the frequency of nodal involve-
ment is low, which is concordant with most previously
reported findings. However, our data is insufficient to
make assertions about the validity of routine sentinel
node evaluation in this group of patients.
We conclude that most of the core biopsy features evalu-
ated herein are of limited value in predicting a close or
positive margin in high and intermediate grade DCIS. A
significant change [to invasive disease (14%) or to no
residual disease (10%)] is seen in approximately 24% of
excisions that follow a core biopsy diagnosis of intermedi-
ate or high-grade DCIS.
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